Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1S | Q13698 | 12/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.71 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | HRH2 | P25021 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | SCN1A | P35498 | 1/20 | 0.71 |
| ▸ | SCN4A | P35499 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.71 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.71 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.71 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.71 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.71 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16756504 | 1.00 | CACNA1S (0.72) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| SCHEMBL1638938 | 1.00 | CACNA1S (0.72) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| SCHEMBL25288373 | 1.00 | CACNA1S (0.72) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL428935 | 0.93 | CACNA1S (0.85) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| SCHEMBL8973326 | 0.93 | CACNA1S (0.72) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Acetic Acid SCHEMBL4447699 | 0.86 | CACNA1S (0.75) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Acetic Acid SCHEMBL4447700 | 0.86 | CACNA1S (0.75) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Acetic Acid SCHEMBL8822753 | 0.86 | CACNA1S (0.75) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| SCHEMBL7348976 | 0.85 | CACNA1S (0.79) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| SCHEMBL7273620 | 0.85 | CACNA1S (0.79) | CACNA1SCYP3A4TSHRABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078873-B2 | Compositions and methods for preventing cardiac arrhythmia | CORMATRIX CARDIOVASCULAR, INC. (US) | 2015-07-14 | — | — | US | claimed |
| US-20150150913-A1 | Compositions and Methods for Preventing Cardiac Arrhythmia | CORVIVO CARDIOVASCULAR, INC. | 2015-06-04 | — | — | US | claimed |
| EP-4744654-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | Anavex Life Sciences Corp. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250281447-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | ANAVEX LIFE SCIENCES CORP. | 2025-09-11 | — | — | US | disclosed |
| US-12280034-B2 | Sigma-1 receptor agonist systolic blood pressure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250032443-A1 | TREATMENT OF MYOTONIC DISORDERS | UNIVERSITY OF ROCHESTER (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2023086854-A1 | TREATMENT OF MYOTONIC DISORDERS | UNIVERSITY OF ROCHESTER (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11622955-B2 | Sigma-1 receptor agonist systolic blood pressure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20230071766-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | ANAVEX LIFE SCIENCES CORP. (US) | 2023-03-09 | — | — | US | disclosed |
| US-20210186920-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | ANAVEX LIFE SCIENCES CORP. (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032443-A1 | TREATMENT OF MYOTONIC DISORDERS | ATP2A3, ATP2A1, ATP2A2 | CACNA1S 38/4885CYP3A4 4831/4885TSHR 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.